Date | Title | Description | Source |
19.03.2024 | NGM Bio to Present Two Posters Highlighting Clinical Data fr... | SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bi... | einpresswi... |
11.03.2024 | NGM Bio Provides Recent Business Highlights and Reports Four... | --Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Pha... | einpresswi... |
11.03.2024 | NGM Bio Provides Recent Business Highlights and Reports Four... | - | globenewsw... |
26.02.2024 | NGM to go private as part of $135M buyout by VC firm Column ... | Following a year that saw a third of staff laid off and a sliding share price, NGM Bio has decided t... | fiercebiot... |
20.02.2024 | NGM Bio to Participate in the Cowen 44th Annual Health Care ... | SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq:... | einpresswi... |
25.05.2023 | NGM Bio to Participate in Upcoming Investor Conferences | /EIN News/ -- SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, ... | einpresswi... |
08.05.2023 | NGM Bio Announces Presentation of Data from Phase 2 Investig... | Aldafermin demonstrated statistically significant reductions in serum 7αC4 (a marker of bile acid sy... | einpresswi... |
04.05.2023 | NGM Bio Reports First Quarter 2023 Financial Results and Pro... | Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvem... | einpresswi... |
25.03.2023 | Her doctor said her severe morning sickness was all in her h... | Taped above a tidy wooden desk in the corner of her bedroom, right at eye level, is a piece of paper... | channelnew... |
04.11.2022 | NGM Bio Announces Poster Presentation Featuring Preclinical ... | /EIN News/ -- --Poster presentation to showcase NGM Bio’s in vitro and in vivo research supporting d... | einpresswi... |
17.10.2022 | NGM Bio’s Merck-partnered drug for vision loss disorder flun... | After NGM Biopharmaceuticals’ most advanced internal program flunked a mid-stage study last year, th... | medcitynew... |
17.10.2022 | NGM Bio Announces Topline Results from the CATALINA Phase 2 ... | Trial did not meet primary endpoint of statistically significant rate of change in GA lesion area us... | globenewsw... |
16.10.2022 | NGM Bio to Host Conference Call to Discuss Topline Results f... | SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio... | globenewsw... |
13.09.2022 | NGM Bio Presents Updated Preliminary Findings from the Ongoi... | NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potentia... | globenewsw... |
06.09.2022 | NGM Bio Presents Updated Preliminary Findings for a Subgroup... | NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potentia... | globenewsw... |
15.08.2022 | NGM Bio Announces Presentations Featuring Updated Findings f... | Poster presentation at upcoming ESMO Annual Congress to highlight analysis of subgroup of patients w... | globenewsw... |
04.08.2022 | NGM Bio Provides Business Highlights and Reports Second Quar... | --Initiated Phase 1/1b clinical trial of NGM438, a LAIR1 antagonist antibody product candidate, as a... | globenewsw... |
30.06.2022 | NGM Bio Appoints Siobhan Nolan Mangini to President and Chie... | -- William J. Rieflin to transition from Executive Chairman to Chairman of the Board of Directors --... | globenewsw... |
23.06.2022 | NGM Bio to Host the Final of Four Virtual R&D Events on ... | --NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3 for t... | globenewsw... |
24.05.2022 | NGM Bio to Host the Third of Four Virtual R&D Events on ... | --NGM707, NGM Bio’s most advanced myeloid reprogramming antibody product candidate, will be showcase... | globenewsw... |
12.05.2022 | NGM Bio Announces Initiation of Phase 1/1b Clinical Study of... | --Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist... | globenewsw... |
20.04.2022 | NGM Bio to Host the Second of Four Virtual R&D Events on... | SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bi... | globenewsw... |
08.04.2022 | NGM Bio to Present Late-Breaking Preclinical Research at 202... | ILT2, ILT4, ILT3 and LAIR1 are myeloid checkpoints that may play a central role in establishing an i... | globenewsw... |
31.03.2022 | NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of... | Dose-escalation and dose-expansion trial evaluating potential of NGM831, an ILT3 antagonist antibody... | globenewsw... |
21.03.2022 | NGM Bio to Host the First of Four Virtual R&D Events on ... | --The four-part series titled the “Explorer Series” will showcase NGM Bio’s discovery engine, myeloi... | globenewsw... |
10.01.2022 | NGM Biopharmaceuticals : Bio - JPM 2022 Presentation | TM
Biology-driven discovery. Life-changing medicines.
Corporate Overview
January 2022
NASDAQ: NGM
©2... | marketscre... |
10.01.2022 | NGM Biopharmaceuticals : Bio Corporate Presentation January ... | TM
Biology-driven discovery. Life-changing medicines.
Corporate Overview
January 2022
NASDAQ: NGM
©2... | marketscre... |
10.01.2022 | NGM Bio Outlines 2022 Strategic Priorities Across Its Portfo... | After a transformative year in 2021, NGM Bio enters 2022 with a diverse pipeline of seven disclosed ... | globenewsw... |
06.12.2021 | NGM Bio Announces Clinical Trial Collaboration with Merck Re... | NGM entered into a clinical trial collaboration and supply agreement with Merck to evaluate the pote... | globenewsw... |
06.12.2021 | NGM Bio Announces Clinical Trial Collaboration with Merck Re... | NGM entered into a clinical trial collaboration and supply agreement with Merck to evaluate the pote... | marketscre... |
23.08.2021 | NGM Biopharmaceuticals : Bio Discloses Fourth Oncology Devel... | Publication describes NGM’s discovery of ILT3’s functional ligand, fibronectin, a key component of t... | marketscre... |
22.07.2021 | NGM Biopharmaceuticals : Announces Completion of Enrollment ... | Geographic atrophy is a progressive, irreversible retinal degenerative disease that can lead to blin... | marketscre... |
24.05.2021 | NGM Bio’s NASH drug fails in Phase 2; focus shifts to Merck-... | An experimental NGM Biopharmaceuticals treatment for non-alcoholic steatohepatitis, the fatty liver ... | medcitynew... |
28.04.2021 | NGM BIOPHARMACEUTICALS, INC.
NGM BIOPHARMACEUTICALS INC : C... | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain... | marketscre... |
28.04.2021 | NGM BIOPHARMACEUTICALS, INC.
NGM Announces Nomination of Ro... | SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (... | marketscre... |
04.03.2021 | NGM Bio Provides Business Highlights and Reports Fourth Quar... | • Significant progress made across liver and metabolic diseases, retinal diseases and cancer during ... | globenewsw... |
25.02.2021 | NGM Bio to Present at the Cowen 41st Annual Health Care Conf... | SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (N... | globenewsw... |
13.02.2021 | Another Keytruda combo tops standard of care in advanc... | South San Francisco-based NGM Bio may have underwhelmed with its interim analysis of a key cohort fr... | endpts.com... |
06.01.2021 | Jan 5, 2021 - NGM Bio Announces Pricing of Upsized $125.0 Mi... | - | prospectve... |
19.11.2020 | NGM BIOPHARMACEUTICALS, INC.
NGM Biopharmaceuticals : Inves... | © 2017 Copyright. NMI Holdings Inc.
2020 Virtual Investor Day
Welcome to NMI Holdings, Inc. - 2020 V... | marketscre... |
19.11.2020 | NGM Biopharmaceuticals : Investor Day - Presentation | © 2017 Copyright. NMI Holdings Inc.
2020 Virtual Investor Day
Welcome to NMI Holdings, Inc. - 2020 V... | marketscre... |
25.02.2020 | The future of these 7 biotechs hinges on their ability to tr... | Reuters
Advertisement
There are about 70 drugs in clinical testing for NASH, a fatty liver disease t... | businessin... |
18.07.2013 | NGM Biopharmaceuticals Inks $50M in Series C |
SOUTH SAN FRANCISCO, CA, NGM Biopharmaceuticals announced today the successful completion of a $50... | vcnewsdail... |
18.07.2013 | NGM completes $50M Series C to advance cardio-metabolic ther... | NGM Biopharmaceuticals has rounded up a $50 million Series C financing to advance the development of... | fiercebiot... |
18.06.2013 | MedImmune and NGM Biopharmaceuticals link for research on di... | MedImmune and NGM Biopharmaceuticals link for research on diabetes and obesity
18-06-2013
AstraZenec... | cambridgen... |
07.05.2013 | NGM raises $13M for cardio/metabolic R&D work | NGM Biopharmaceuticals has raised a little more than $13 million of a planned $50 million round, acc... | fiercebiot... |
15.03.2010 | NGM Biopharmaceuticals Closes First Tranche of $51M Series B... | NGM Biopharmaceuticals, Inc., a South San Francisco, California-based company dedicated to the disco... | finsmes.co... |
12.02.2008 | Life sciences briefing: Tuesday, Feb. 12, 2008 | TODAY’S HEADLINES:
Metabolic-disease biotech NGM Biopharma raises $25M (peHUB)
Heart, HIV drug maker... | venturebea... |
- | NGM Bio’s NASH drug fails in Phase 2; focus shifts to Merck-... | An experimental NGM Biopharmaceuticals treatment for non-alcoholic steatohepatitis, the fatty liver ... | medcitynew... |